#USA #Del Mar #mRNA Technology #Phylex BioSciences #Andes hantavirus

Phylex BioSciences Leverages AI for Rapid Vaccine Development

In a groundbreaking announcement, Phylex BioSciences has successfully harnessed the power of artificial intelligence to develop a vaccine in response to the Andes hantavirus outbreak. The company revealed that it took only two working days to design a ready-to-manufacture mRNA nanoparticle vaccine after gaining access to the initial virus sequence provided by Geneva University Hospitals. This unprecedented speed showcases the potential of AI in public health crises, marking a significant milestone in the fight against zoonotic viruses.

The Andes hantavirus, known scientifically as ANDV, has been linked to severe outbreaks, including a recent infection scenario aboard the cruise ship MV Hondius, leading to the evacuation of passengers from multiple countries. Responsible for hantavirus pulmonary syndrome (HPS), ANDV is a respiratory virus that presents a fatality rate as high as 50%. It is primarily transmitted through persistently infected rodents in the mountainous terrains of Argentina and Chile and can also spread from human to human, raising concerns about its public health implications.

Phylex's innovative mRNA nanoparticle technology has previously proven effective against significant viral threats such as SARS-CoV-2, developed in collaboration with the Pasteur Institute in Paris, and the Nipah virus, in partnership with scientists from the US Centers for Disease Control (CDC). The vaccine works by encoding for a nanoparticle that displays 60 optimized copies of the virus's antigen, thereby enhancing the immune response.

Pascal Brandys, co-founder and CEO of Phylex BioSciences, emphasized the company's commitment to rapid vaccine technology. "It took us exactly two working days... to complete the design of a vaccine that can enter manufacturing and in vivo testing immediately. Our research program can respond quickly to this new health threat," he stated.

The accelerated development of the Andes hantavirus vaccine underscores the efficiency of Phylex's AI-driven approach, which integrates deep learning tools to design optimized antigens. The nanoparticle platform not only mimics the virus, thus eliciting a strong immune reaction but is also straightforward to manufacture and distribute, significantly reducing the time frame usually required for vaccine development.

"All our vaccines benefit from the combined advantages of AI-derived accelerated design, mRNA technology for speed of manufacturing and development, and the efficacy of a nanoparticle," Brandys added. This case is a testament to Phylex's capability to adapt and respond to continuously evolving threats posed by viral outbreaks and zoonoses.

Having been established during the onset of the COVID-19 pandemic by genomics expert Pascal Brandys and virologist Jens Herold, Phylex BioSciences is pioneering the development of AI-derived mRNA nanoparticle vaccines aimed at zoonotic diseases. As evidenced by the swift response to the Andes hantavirus outbreak, the company's technology is poised to play a crucial role in safeguarding public health against emerging infectious threats.

The use of AI in vaccine development not only promises faster responses to viral outbreaks but also provides a framework for addressing public health challenges more effectively. Phylex's ongoing efforts serve as a model for future research and development within the field of biotechnology and vaccine production, potentially altering the landscape of infectious disease management.

As the world continues to face emerging infectious diseases, the need for rapid, effective, and innovative vaccine solutions has never been more critical. Phylex BioSciences is at the forefront of this endeavor, showcasing how cutting-edge technology can lead to timely and lifesaving interventions against deadly viruses.